Home » Newsletters » BioWorld Science

BioWorld Science

July 12, 2013

View Archived Issues

Oncothyreon presents results from two phase II studies of PX-866

Researchers describe unique properties of diabetes treatment candidate SKL-18287

Crolibulin combined with cisplatin shows activity in anaplastic thyroid cancer

Recommended phase II dose of MLN-2480 determined in patients with solid tumors

Merck Serono reports results of APRIL-SLE study of atacicept

Macquarie University awarded grant to support development of cancer diagnostics

Astex Pharmaceuticals to submit IND for ASTX-727

Cellectis achieves proof of concept in in vivo testing of curative therapy for leukemia

Serodus ASA to merge with Phlogo ApS

Loxo Oncology and Array BioPharma enter license and collaboration agreement

Emergent BioSolutions completes phase III trial of BioThrax

Roche presents novel RORgamma modulators for arthritis

Cellzome patents new tyrosine-protein kinase inhibitors

FDA to review application seeking new indication for Eliquis

Phase III study of Revlimid in newly diagnosed multiple myeloma meets primary endpoint

CRUISE-1 phase III trial of iron-delivery drug SFP meets primary endpoint

BARDA releases additional funding to support BioCryst filing of peramivir NDA

pSivida discloses interim data from investigator-sponsored study of micro-insert in uveitis

Boehringer Ingelheim divulges novel reverse transcriptase inhibitors

ProMetic set to advance lead antifibrotic drug candidate PBI-4050 to clinic

Scientists at Roche synthesize new PAK 1 inhibitors

Merck KGaA designs novel PAMs of muscarinic M1 receptor

Ultragenyx obtains worldwide license for triheptanoin

Biodel completes dosing in phase II trial of ultra-rapid-acting injectable mealtime insulin BIOD-123

Mitsubishi Tanabe Pharma to acquire Medicago

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...